LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part B - Behavioral results

    2009  Volume 17

    Abstract: Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who ... ...

    Abstract Abstract Background This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R 2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 150
    Language English
    Publishing date 2009-10-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

    Gehn Eva / Newmark Sanford / Zappia Irene / Hensley Andrea / Ingram Julie / Mitchell Jessica / Geis Elizabeth / Baral Matthew / Adams James B / Rubin Robert A / Mitchell Ken / Bradstreet Jeff / El-Dahr Jane

    BMC Clinical Pharmacology, Vol 9, Iss 1, p

    Part A - Medical results

    2009  Volume 16

    Abstract: Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Abstract Background This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years. Methods Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation. Conclusion Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    Keywords Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Language English
    Publishing date 2009-10-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Volume 9, Page(s) 17

    Abstract: Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.: Methods: Phase 1 involved 65 children with ASD who received ... ...

    Abstract Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.
    Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94).
    Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
    MeSH term(s) Adaptation, Psychological/drug effects ; Aging ; Autistic Disorder/classification ; Autistic Disorder/complications ; Autistic Disorder/drug therapy ; Chelating Agents/adverse effects ; Chelating Agents/therapeutic use ; Child ; Child Behavior/drug effects ; Child, Preschool ; Drug Administration Schedule ; Glutathione/blood ; Heavy Metal Poisoning, Nervous System/complications ; Humans ; Metals, Heavy/toxicity ; Metals, Heavy/urine ; Parents/psychology ; Psychiatric Status Rating Scales ; Regression Analysis ; Succimer/adverse effects ; Succimer/therapeutic use ; Surveys and Questionnaires ; Treatment Outcome
    Chemical Substances Chelating Agents ; Metals, Heavy ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Language English
    Publishing date 2009-10-23
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

    Adams, James B / Baral, Matthew / Geis, Elizabeth / Mitchell, Jessica / Ingram, Julie / Hensley, Andrea / Zappia, Irene / Newmark, Sanford / Gehn, Eva / Rubin, Robert A / Mitchell, Ken / Bradstreet, Jeff / El-Dahr, Jane

    BMC clinical pharmacology

    2009  Volume 9, Page(s) 16

    Abstract: Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.: Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants ... ...

    Abstract Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.
    Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
    Results: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.
    Conclusion: Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.
    MeSH term(s) Administration, Oral ; Autistic Disorder/blood ; Autistic Disorder/drug therapy ; Autistic Disorder/urine ; Blood Cell Count/methods ; Child ; Child, Preschool ; Double-Blind Method ; Female ; Glutathione/blood ; Glutathione/urine ; Humans ; Male ; Metals/blood ; Metals/urine ; Succimer/administration & dosage ; Succimer/adverse effects ; Treatment Outcome
    Chemical Substances Metals ; Succimer (DX1U2629QE) ; Glutathione (GAN16C9B8O)
    Language English
    Publishing date 2009-10-23
    Publishing country England
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041488-2
    ISSN 1472-6904 ; 1472-6904
    ISSN (online) 1472-6904
    ISSN 1472-6904
    DOI 10.1186/1472-6904-9-16
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top